MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia"

  • 2019 International Congress

    Encephalomyelopathy Due to Cerebrotendinous Xanthomatosis

    ACO. Oliveira, LFV. Vasconcellos, BXC. Cordeiro, LLN. Najar (Rio de Janeiro, Brazil)

    Objective: To present a case in which the MRI of a patient with cerebrotendinous xanthomatosis (CTX)  revelaled impairment of whole neuroaxis. Background: CTX is a…
  • 2019 International Congress

    Higher probability of prodromal Parkinson’s disease is related to lower performance in all cognitive domains

    A. Bougea, M. Maraki, M. Yannakoulia, M. Stamelou, G. Xiromerisiou, M. Kosmidis, E. Dardiotis, G. Hadjigeorgiou, P. Sakka, C. Anastasiou, L. Stefanis, N. Scarmeas (Athens, Greece)

    Objective: to assess prodromal Parkinson disease (PD) probability and relate it to detailed cognitive performance in a community cohort. Background: There is a limited information…
  • 2019 International Congress

    Antipsychotics Use in Parkinson’s Disease and Mortality Risks

    WM. Liu, JH. Wang, HY. Chen, R. Lo (Hualien, Taiwan)

    Objective: To describe the use of antipsychotics in patients with Parkinson’s disease (PD) and study its associated mortality risks. Background: The US Food and Drug…
  • 2019 International Congress

    Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population

    J. Wetmore, H. Yan, M. Irfan, Y. Peng, D. Gilbertson, S. Li, N. Rashid, A. Shim (Minneapolis, MN, USA)

    Objective: To describe healthcare resource use (HCRU) and related costs among Parkinson’s patients with dementia (PDD) and psychosis compared with other dementia types in a…
  • 2019 International Congress

    Clinical and neuroimaging heterogeneity of dementia with Lewy bodies

    A. Chimagomedova, E. Vasenina, O. Levin (Moscow, Russian Federation)

    Objective: To study clinical and neuroimaging features of dementia with Lewy bodies (DLB) for optimal management and prognosis of the disease. Background: Appropriate diagnosis of DLB…
  • 2019 International Congress

    Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain

    K. Methawasin, R. Suppawat, P. Petborom, M. Wongwandee, S. Rungruanghiranya, T. Asawavichienjinda (Ongkharak, Thailand)

    Objective: To find out phenotypes of movement disorders related to COPD, and also associated factors. Background: Movement disorders in systemic diseases exactly are common in…
  • 2019 International Congress

    Nutritional status in patients with Parkinson’s disease and its relationship with the motor phenotype.

    R. Cruz, J. Balderas, C. Navarro, L. Zuazua, M. Rodriguez, A. Cervantes (Mexico City, Mexico)

    Objective: To determine the nutritional status in patients with Parkinson's disease and to relate it to the motor phenotype. Background: Parkinson disease (PD) is a…
  • 2019 International Congress

    MCI reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease

    SJ. Chung, Y-H. Park, YH. Sohn, J-M. Lee, PH. Lee (Seoul, Republic of Korea)

    Objective: To investigate whether reversion to cognitively normal status (CogN) is clinically relevant in Parkinson’s disease with mild cognitive impairment (PD-MCI). Background: The concept of…
  • 2019 International Congress

    Number of people with Parkinson’s dementia in New Zealand

    T. Pitcher, D. Myall, J. Dalrymple-Alford, M. Macaskill, T. Anderson (Christchurch, New Zealand)

    Objective: To estimate the number of people with Parkinson’s disease dementia (PDD) in New Zealand and how this has changed over time. Background: People with…
  • 2019 International Congress

    Serum uric acid levels and cognitive function in Parkinson’s disease

    J. Difrancisco-Donoghue, W. Werner, B. Krishnamachari, K. Arabian, E. Thomas, D. Granger, R. Gallagher (Irvine, CA, USA)

    Objective: To compare serum uric acid (sUA) levels in Parkinson’s disease (PD) subjects to cognitive function. Background: Reduced sUA levels have been reported in individuals…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 33
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An atypical and interesting feature of Parkinson´s disease
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley